BICX on OTC
BioCorRx Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Elite Health Systems Inc., Concentra Group Holdings Parent, Inc. or Acadia Healthcare, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development31¢$1.8M
- Selling, general and admin66¢$3.8M
- Interest4¢$223.8K
Out of $797.2K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues, net | $797.2K | $7.7K |
| Cost of implants and other costs | $21.8K | $1.7K |
| Research and development | $1.8M | $1.5M |
| Selling, general and administrative | $3.8M | $3.6M |
| Depreciation and amortization | $44.0K | $33.1K |
| Total operating expenses | $5.6M | $5.1M |
| Loss from operations | -$4.8M | -$5.1M |
| Interest expense - related parties | -$637.7K | -$750.8K |
| Interest expense, net | -$223.8K | -$776.8K |
| Loss on settlement of debt | -$187.5K | -$164.6K |
| Grant income | $2.4M | $1.5M |
| Change in fair value of upfront purchase price liability | -$7.4K | $0 |
| Change in fair value of royalty liability | -$279.5K | $0 |
| Other miscellaneous income | $223.0K | $129.3K |
| Total other (expenses) income, net | $1.3M | -$89.6K |
| Loss before provision for income taxes | -$3.5M | -$5.2M |
| Income taxes | $0 | $0 |
| Net loss | -$3.5M | -$5.2M |
| Non-controlling interest | $68.6K | $106.0K |
| Net loss attributable to BioCorRx Inc. | -$3.4M | -$5.1M |
| Net loss per common share, basic and diluted | -$0.19 | -$0.49 |
| Weighted average number of common shares outstanding, basic and diluted | 18.5M shares | 10.5M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|
| Cash | $139.4K | $287.7K | $88.0K |
| Accounts receivable, net | $253.5K | $0 | |
| Grant receivable | $52.0K | $0 | |
| Inventory | $143.4K | $0 | |
| Prepaid expenses | $226.2K | $30.0K | |
| Total current assets | $814.5K | $118.0K | |
| Property and equipment, net | $4.1K | $19.0K | |
| Right to use assets | $159.1K | $199.2K | |
| Intangible assets, net | $564.5K | $7.8K | |
| Goodwill | $563.2K | $0 | |
| Deposits, long term | $41.9K | $41.9K | |
| Total other assets | $1.2M | $49.8K | |
| Total assets | $2.1M | $385.9K | |
| Accounts payable and accrued expenses, including related party payables of $1,271,685 and $1,349,465, respectively | $6.4M | $5.6M | |
| Deferred revenue, grant | $0 | $56.6K | |
| Lease liability, short term | $43.4K | $40.1K | |
| Notes payable, net of debt discount of $0 and $41,452, respectively | $1.2M | $1.3M | |
| Notes payable, related parties, net of debt discount of $0 | $677.4K | $1.2M | |
| Total current liabilities | $8.3M | $8.2M | |
| Economic Injury Disaster loan, long term | $69.5K | $71.0K | |
| Royalty obligation, net of discount of $3,941,262 and $4,418,698, related parties | $4.8M | $4.3M | |
| Upfront purchase price liability | $42.5K | $0 | |
| Royalty liability | $359.4K | $0 | |
| Lease liability, long term | $115.7K | $159.1K | |
| Total liabilities | $13.7M | $12.7M | |
| Common stock, $0.001 par value; 750,000,000 shares authorized, 24,489,311 and 13,299,349 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $24.5K | $13.3K | |
| Common stock subscribed | $100.0K | $100.0K | |
| Additional paid in capital | $75.3M | $71.0M | |
| Accumulated deficit | -$86.6M | -$83.2M | |
| Total deficit attributable to BioCorRx, Inc. | -$11.2M | -$12.1M | |
| Non-controlling interest | -$303.4K | -$234.8K | |
| Total deficit | -$11.5M | -$12.4M | |
| Total liabilities and deficit | $2.1M | $385.9K | |
| Related party payables | $1.3M | $1.3M | |
| Debt discount on notes payable | $0 | $41.5K | |
| Related party debt discount on notes payable | $0 | ||
| Discount on Royalty obligation related parties | $3.9M | $4.4M | |
| Preferred Stock, Shares Authorized | 600.0K shares | 600.0K shares | |
| Common Stock, Par Value | $0.00 | $0.00 | |
| Common Stock, Shares Authorized | 750.0M shares | 750.0M shares | |
| Common Stock, Shares Issued | 24.5M shares | 13.3M shares | |
| Common Stock, Shares Outstanding | 24.5M shares | 13.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$3.5M | -$5.2M |
| Depreciation and amortization | $44.0K | $33.1K |
| Amortization of discount on royalty obligation | $477.4K | $480.7K |
| Amortization of debt discount | $55.7K | $621.5K |
| Amortization of right-of-use asset | $40.1K | $62.1K |
| Loss on settlement of debt | $187.5K | $164.6K |
| Change in fair value of upfront purchase price liability | $7.4K | $0 |
| Change in fair value of royalty liability | $279.5K | $0 |
| Other income | $0 | -$32.4K |
| Stock based compensation | $592.6K | $1.2M |
| Imputed interest for related party advances | $36.4K | $43.9K |
| Warrants issued in connection with the Sales Representative Agreement | $4.4K | $0 |
| Accounts receivable | -$253.5K | $740 |
| Grant receivable | -$52.0K | $76.3K |
| Inventory | -$9.8K | $0 |
| Prepaid expenses | -$32.1K | $14.9K |
| Accounts payable and accrued expenses | $286.8K | $1.4M |
| Deposits | $0 | $2.6K |
| Upfront purchase price liability | -$357.4K | $0 |
| Lease liability | -$40.1K | -$66.1K |
| Deferred revenue | $0 | -$4.0K |
| Deferred revenue, grant | -$56.6K | $56.6K |
| Net cash used in operating activities | -$2.3M | -$1.1M |
| Proceeds from common stock subscription and royalty agreement | $1.9M | $0 |
| Payment to Economic Injury Disaster loan | -$1.5K | -$1.4K |
| Payment of notes payable - related party | -$525.7K | -$11.0K |
| Payment of notes payable | -$150.0K | $0 |
| Proceeds from notes payable | $0 | $200.0K |
| Proceeds from notes payable - related party | $1.1M | $931.5K |
| Net cash provided by financing activities | $2.3M | $1.1M |
| Net increase (decrease) in cash | $51.3K | $22.8K |
| Interest paid | $521.4K | $10.7K |
| Taxes paid | $0 | $0 |
| Common stock issued in connection with issuance of promissory notes | $36.8K | $213.3K |
| Common stock issued in connection subscription agreement | $0 | $9 |
| Record right to use assets per ASC 842 | $0 | -$225.7K |
| Record lease liability per ASC 842 | $0 | $225.7K |
| Common stock issued in connection with APA (Note 4) | $153.5K | $0 |
| Warrants issued in connection with APA (Note 4) | $89.8K | $0 |
| Common stock issued in connection with conversion of promissory notes and accounts payable | $1.4M | $1.2M |
| Derivative liability recognized in connection with issuance of promissory notes | $0 | $26.7K |
| Warrants issued in connection with issuance of promissory notes | $0 | $83.6K |
Former names
Recent filings
- Sep 4, 20268-K
- Aug 14, 202610-Q
- May 15, 202610-Q
- Apr 2, 20268-K
- Mar 31, 202610-K
- Nov 14, 202510-Q
- Aug 14, 202510-Q
- Aug 1, 20258-K
- May 15, 202510-Q
- Mar 31, 202510-K
- Mar 11, 20258-K
- Jan 31, 20254
- Jan 31, 20254
- Nov 14, 202410-Q
- Aug 13, 202410-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBioCorRx Inc. filings on SEC EDGAR
- 2SEC EDGARBioCorRx Inc. filings on SEC EDGAR
- 3SEC EDGARBioCorRx Inc. 10-K for fiscal 2025
- 4SEC EDGARBioCorRx Inc. 10-K for fiscal 2019
- 5SEC EDGARBioCorRx Inc. 10-K for fiscal 2020
- 6SEC EDGARBioCorRx Inc. 10-K for fiscal 2021
- 7SEC EDGARBioCorRx Inc. 10-K for fiscal 2022
- 8SEC EDGARBioCorRx Inc. 10-K for fiscal 2023
- 9SEC EDGARBioCorRx Inc. 10-Q for fiscal 2025
- 10SEC EDGARBioCorRx Inc. 10-Q for fiscal 2026
- 11SEC EDGARBioCorRx Inc. 10-Q for fiscal 2026